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Georgios Stamatis, MD,‡ Ju¨rgen R. Fischer, MD,§ and Jens A. Koch, MD,¶ and Michael Stahl, MD*
Background: Bendamustine is an alkylating agent with hybrid
activity and proven efficacy in small-cell lung cancer associated
with a favorable toxicity rate. This phase II study of carboplatin/
bendamustine was conducted to evaluate the efficacy of this
combination in patients with extensive disease small-cell lung
cancer (ED-SCLC).
Methods: Fifty-six untreated patients with ED-SCLC were enrolled.
Their median age was 63 years. Sixty-seven percent of patients were
male and 18% had a World Health Organization performance status
of 2. Bendamustine was administered as a 30- to 60-minute infusion
at a dose of 80 mg/m2 on days 1 and 2, and carboplatin was given
at an area under the curve of 5 on day 1 of a 21-day cycle.
Results: Fifty-five patients were assessable for response and toxic-
ity. The overall response rate was 72.7% (95% confidence interval:
59%–84%), with one complete remission (1.8%). The median time
to progression was 5.2 months (95% confidence interval: 4.2–5.6).
At the time of evaluation, 71% of the patients had died. The median
survival time reached 8.3 months (95% confidence interval: 6.6–
9.9). The major toxicity of this regimen was myelosuppression,
including grade 3 or 4 neutropenia (46%), thrombopenia (26%),
anemia (15%), and infections (11%). Toxic death was recorded in
two patients (3.6%).
Conclusions: The carboplatin/bendamustine regimen is a well-
tolerated cytostatic combination in ED-SCLC with activity compa-
rable with that of other platinum-based regimens. Further investiga-
tions, such as a phase III trial, are currently planned.
Key Words: Small cell lung cancer, Chemotherapy, Extensive
disease.
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Small-cell lung cancer constituted approximately 15% ofthe estimated 381,500 lung cancer patients in Europe in
2004.1 Despite great efforts being put into improving diag-
nostic and treatment approaches, the vast majority of these
patients eventually die of metastatic disease due to tumor
progression or recurrence after initial response.2–4 Because
almost all the patients develop small-cell lung cancer because
of tobacco smoking,5 they may often have comorbidities of
the cardiovascular system that prevent the use of various
cytotoxic agents, e.g., cisplatin and anthracyclins.
Bendamustine (bendamustine hydrochloride) is an al-
kylating agent with a hybrid mode of action. Compared with
classic alkylators, the induced DNA double-strand breaks are
more long-lasting6 and are repaired by base excision repair
rather than by the alkylguanine transferase mechanism.7 In
vitro and in vivo data suggest only partial cross-resistance to
alkylators (cyclophosphamide, chlorambucil, melphalan), an-
thracyclines (doxorubicin), and podophyllotoxins (etopo-
side).8 When analyzed in the National Cancer Institute De-
velopmental Therapeutics Program database,7 bendamustine
shows a lack of activity correlation to other drugs presented
there. This distinctly unique mechanism of action in compar-
ison with other cytotoxic agents might be due to a specific
gene signature regulated by bendamustine.8
Recently, the compound has attracted renewed interest,
and a whole range of preclinical and clinical trials were
initiated. A multitude of phase II clinical studies evaluated
bendamustine’s activity in hematologic malignancies.9–16 In
more recent studies, activity was also demonstrated in pa-
tients with solid tumors such as lung, breast, and germ cell
cancers.17–22
To establish a new combination chemotherapy that may
offer both favorable toxicity and high antitumor efficacy, we
investigated bendamustine and carboplatin in a dose-finding
study, which has been published elsewere.17 To confirm these
promising results, a phase II study in patients with extensive
disease small-cell lung cancer (ED-SCLC) was performed.
PATIENTS AND METHODS
Patient Selection
The experimental investigation of patients reported in
this article was performed with informed consent and follow-
ing all the guidelines for experimental investigation with
human subjects. Patients with histologically or cytologically
confirmed extensive disease small-cell lung cancer (ED-SCLC)
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were assessed for eligibility. Previous radiation therapy or
cytotoxic treatment was not allowed. Furthermore, patients
needed to meet the following criteria to be eligible: bidimen-
sionally measurable disease as defined by World Health
Organization (WHO) criteria; age between 18 and 75 years;
performance status (WHO) 0–2; adequate hematologic func-
tion (leukocytes 4000/l, platelets 120,000/l), normal
renal (serum creatinine) and hepatic function (serum glutamic
oxaloacetic, serum glutamic pyruvate transaminase, and bil-
irubin, with the exception of increased liver enzymes due to
liver metastases); decompensated cardiac function; preg-
nancy or lactation; inadequate contraception; and second
malignancy. Patients with brain metastases were not eligible.
All patients provided written informed consent according to
federal and institutional guidelines. The study was approved
by the local ethics committee of the participating centers.
Treatment
Bendamustine 80 mg/m2 was administered by intrave-
nous infusion over 30 to 60 minutes on days 1 and 2, e.g., 21
days. Carboplatin was given by intravenous infusion (30–60
minutes) on day 1 of each cycle at a dose resulting in an area
under the curve of 5 calculated according to the Calvert’s
formula. Oral antiemetic therapy consisting of a serotonin
5-HT3 receptor antagonist, corticosteroid, and metoclopra-
mide was recommended. Dose reduction was based on tox-
icity according to National Cancer Institute Common Toxic-
ity Criteria version 2.0. In case of grade 4 leuko- or
thrombocytopenia, the dose of bendamustine was reduced to
60 mg/m2. The patients were to undergo at least two cycles of
chemotherapy. In case of no further tumor progression after
two cycles and of objective response after four cycles, pa-
tients were to be treated for up to six cycles of chemotherapy.
A delay of treatment up to 2 weeks was permitted. Follow-up
of the patients was performed at 6-week intervals until tumor
progression or death.
Study Evaluations
Pretreatment evaluation included a complete medical
history and physical examination. Further diagnostic evalua-
tion included complete blood count and routine chemistry
panel, electrocardiogram, chest radiograph, computed tomog-
raphy of the thorax, abdomen, and neurocranium. The blood
count was repeated at weekly intervals throughout the course
of treatment. Medical history, physical examination, and
laboratory tests were repeated before each cycle. Tumor
response was assessed by computed tomography scans every
two cycles. Patients received a minimum of two cycles unless
unacceptable toxicity or early progression of disease oc-
curred. Toxicity was evaluated after each cycle and during
follow-up according to National Cancer Institute Common
Toxicity Criteria. Patients were evaluated for response ac-
cording to WHO criteria after two successive cycles. In brief,
complete remission was defined as complete disappearance of
all tumor lesions observed for a minimum of 4 weeks. Partial
response was defined as decrease in the sum of the products
of all index lesions of at least 50% for a minimum of 4 weeks
without appearance of new metastases. Progressive disease
was defined as increase of at least 25% of measurable tumor
or occurrence of new lesions.
Statistical Methods
The primary end point of this study was the objective
response rate (complete and partial response). This trial was
conducted by using a one-step design according to Fleming23
to test the null hypothesis that the response rate was less than
45%. The significance level of   0.05 was defined at a
power of 90%. To fulfill these numbers, 51 patients had to be
included into this phase II evaluation. Secondary end points
of the study were the evaluation of toxicity, remission dura-
tion, progression free survival, and overall survival. Remis-
sion duration and survival times were calculated by using the
Kaplan-Meier method. Complete remission was calculated
from the first time to be observed until tumor progression;
partial response was calculated from the first day of treatment
until tumor progression; progression-free survival was de-
fined as the interval from the first day of treatment up to
tumor progression or the last date of observation without
tumor progression. Overall survival was calculated from the
first day of treatment until death of any cause; living patients
were censored at the last date of follow-up.
RESULTS
Patient Characteristics
Fifty-six patients with ED-SCLC from six centers were
enrolled into this phase II trial from February 2001 to May
2005. Study evaluation was done on May 31, 2006. At this
time, the median follow-up for surviving patients was 15.5
months. One patient was not eligible due to impaired renal
function and a performance status below WHO grade 2. The
baseline patients and disease characteristics of the 55 assess-
able patients are listed in Table 1. Thirty-seven patients
(76%) were male. Two thirds of the patients had a history of
significant cardiovascular disease; however, most of them
(60%) had good performance status at the start of therapy. All
patients showed extensive disease stage, with 91% of them
having extrathoracic disease. A total of 238 cycles were
delivered with a median of four cycles. Two patients received
only one cycle because of early death. Another two patients
died possibly due to treatment-related complications (fever
and suspicion of pneumonia). Eighteen patients (33%) re-
ceived all six cycles.
Toxicity
Grade 3 and 4 toxicities were mainly caused by my-
elosuppression. Forty-six percent of the patients developed
grade 3 and 4 leukopenia and 26% demonstrated grade 3 and
4 thrombocytopenia during treatment (Table 2). Nonhemato-
logic side effects were moderate and reversible after therapy.
Of note, only four patients (7%) had of grade 1 peripheral
neuropathia due to chemotherapy. Myelosuppression, prefer-
ably thrombocytopenia, caused treatment delays, increasing
with cycles delivered. A prolongation of 6.8 days (median)
after the second cycle and of 9.1 days after the fourth cycle,
respectively, was observed. Nevertheless, in those patients
receiving all planned six cycles, the mean dose of bendamus-
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tine in cycle 6 (18 patients) was 96.5% of that in cycle 1 (55
patients). Early death during chemotherapy occurred in five
patients (9.1%), which was possibly treatment related in
two patients (3.6%), tumor related in two patients, and due
to intercurrent cardiac disease in one patient. Another six
patients discontinued the treatment on the decision of the
treating physician. All of them had protracted thrombocyto-
penia. Alopecia was very rare (9%), and only one patient
developed grade 2 hair loss.
Response and Survival
All 55 patients were included into an intention-to-treat
analysis for response. Best response was confirmed as CR in
one (1.8%) and partial response in 39 (70.9%) patients,
respectively, for an overall response rate of 73% (95% con-
fidence interval: 59–84). One patient demonstrated disease
progression during treatment. At time of analysis, 51 of 55
patients had died. The median duration of response was 5.5
months with the CR still lasting for more than 33 months. The
median time to tumor progression reached 5.2 months (95%
confidence interval: 4.2–5.6) (Figure 1). The median survival
time (Kaplan-Meier estimation) was 8.3 months (95% CI:
6.6–9.6), and the 1-year survival rate was 18.2% (Figure 2).
DISCUSSION
SCLC is one of the most aggressive tumor entities in
oncology. Chemotherapy is the cornerstone of therapeutic
strategy for ED.3 Despite high response rates to initial che-
motherapy, the majority of ED-SCLC patients will relapse
within 6 months of completing therapy. The outlook for














Extensive disease I 5 9
Extensive disease II 50 91
LDH
Upper normal limit 43 78





*The following locations were defined as separate metastatic sites: cervical lymph
nodes, abdominal lymph nodes, lung, liver, bone, and adrenal gland. WHO, World
Health Organization; LDH, lactate dehydrogenase.
TABLE 2. Worst Toxicity per Patient According to Common










Anemia 23 (42) 23 (42) 8 (15) 0
Leukopenia 7 (13) 15 (27) 22 (40) 3 (6)
Neutropenia 13 (24) 10 (18) 10 (18) 5 (9)
Thrombocytopenia 24 (44) 9 (16) 8 (15) 6 (11)
Infection 0 11 (20) 4 (7) 2 (4)
Nonhematologic
Nausea 14 (26) 7 (13) 1 (2) 0
Vomiting 6 (11) 5 (9) 0 0
Diarrhea 4 (7) 2 (4) 0 0
Stomatitis 3 (6) 0 0 0
Alopecia 4 (7) 1 (2) 0 0
Creatinine 4 (7) 1 (2) 0 0
Neuropathia 4 (7) 0 0 0
FIGURE 1. Kaplan-Meier estimation of time to tumor pro-
gression. Median time to tumor progression was 5.2 months
(95% confidence interval: 4.2–5.6).
FIGURE 2. Kaplan-Meier estimation of overall survival. Me-
dian overall survival was 8.3 months (95% confidence inter-
val: 6.6–9.6), and the 1-year survival rate was 18.2%.
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patients who receive second-line chemotherapy is still very
poor.4 Responses are brief, and median survival is in the
range of 3 to 6 months. Details concerning our patients who
received a subsequent treatment following first-line chemo-
therapy are not available retrospectively and could not be
collected. Cisplatin plus etoposide is the most widely used
regimen, although it has demonstrated increased efficacy
compared with non–platinum-containing regimens only in
some studies with patients with limited disease.24 A Japanese
study proved a significant survival advantage with cisplatin/
irinotecan compared with the cisplatin/etoposide regimen.25
However, the treatment benefit of topoisomerase I inhibitors
plus cisplatin could not be confirmed in subsequent trials in
the United States and Europe.26–28 Some other novel cyto-
toxic drugs, e.g., taxanes and gemcitabine, have been recently
investigated in combination with cisplatin or carboplatin in
phase II and III trials (Table 3). In summary, these combina-
tions induced response rates of 38%–84% in patients with
ED, resulting in median survival times of 7.2–12.8 months
and 1-year survival rates of 30%–58%.29–34 The differences
in response rates and survival times may be rather due to
patients selection than to efficacy of the specific combination.
In addition to younger age, good performance status, female
sex, and normal serum lactate dehydrogenase levels are
usually accepted as favorable prognostic factors in patients
with ED-SCLC.5
In our trial, results with regard to response and median
survival compare well with those in the literature (Table 3).
Although we observed only one complete remission, more
than 70% of patients demonstrated an objective response to
treatment, and a response duration of 5.5 months is well in
line with other combinations in ED. This also holds true for
the median survival time (8.3 months). However, the 1-year
survival rate of 18.2% was rather low. This appears not to be
explained by the patient population included into the trial.
The median age of 63 years compared well, and the number
of patients with reduced performance status (18%) or male
sex (67%) was comparable with that in other trials (Table 3),
although the number of patients with increased lactate dehy-
drogenase (78%) was somewhat higher. One can speculate
that the poor survival rate at 1 year may be due to a small
number of patients undergoing second-line treatment. How-
ever, we do not have enough data from our trial, and most of
the other studies do not report on second-line treatment
either. Therefore, whether the low-toxicity combination of
carboplatin/bendamustine will definitely cause less chance of
a 1-year survival can only be proved by a prospective,
randomized phase III trial.
In addition to the great variability in treatment efficacy,
recent platinum-based cytostatic combinations also signifi-
cantly differ in frequency and severity of side effects. Grade
3 and 4 vomiting or diarrhea was reported in 15%–30% of the
patients with combinations including paclitaxel or irinote-
can.35 In our trial, severe nonhematologic toxicities were not
observed, and there was no increase in the severity of side
effects with an increased number of cycles. Although the
treatment intervals had to be prolonged, the average dose of
both drugs was kept above 95% in cycle 6. Even hematologic
toxicities were also less severe than those reported from other
combinations. Severe myelosuppression, mainly leukocyto-
penia, was recorded in less than 50% of the patients, and
approximately 10% had severe infections. Nevertheless, leu-
kopenia proved to be prolonged and cumulative and was
responsible for five patients to go off study after their third to
fifth cycles. In contrast to studies with irinotecan, topotecan,
or paclitaxel, moreover, alopecia caused by bendamustine
was negligible (9% WHO I/II) after the application of car-
boplatin/bendamustine.
From the results of our study, it can be concluded that
the combination of carboplatin/bendamustine is active and
generally well tolerated in patients with ED-SCLC. In par-
ticular, the nonhematologic toxicity rates are very low and the
regimen is not contraindicated in patients with cardiovascular
TABLE 3. Results of Prospective Studies with Modern Platinum-based Combinations in





Good PS* % CR % OR OS (mo)
Cis/Iri# (7) 77 18 97 2.6 84.4 12.8
Cis/Iri (9) 15 7 100 0 80 9.4
Cis/Topo (10) 41 29 83 2.4 63.4 9.6
Cis/Topo (11) 42 21 100 11.9 61.9 8.7
Carbo/Gem (12) 66 51 87 3.0 42.5 9.2
Carbo/Pac§ (13) 66 49 56 1.5 37.9 7.2
Carbo/E/Pac (14) 50 7 80 20 74 9.1
Cis/E/Pac# (15) 283 55 96 16 74.8 10.6
Cis/Ifo/Pac (16) 35 37 86 14.7 70.6 9.5
Carbo/Benda (current trial) 55 33 82 1.8 72.2 8.3
CR, complete remission; OR, objective remission; OS, median overall survival; Cis, cisplatin; Iri, irinotecan; Topo,
topotecan; Carbo, carboplatin; Gem, gemcitabine; Pac, paclitaxel; E, etoposide; Ifo, ifosfamide; Benda, bendamustine.
*Performance status 0–1 according to World Health Organization criteria.
#Phase III study.
§Only patients with performance status of Eastern Cooperative Oncology Group grade 2 or age older than 70 years.
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disease. Therefore, we are going to investigate this regimen
further in a prospective, randomized phase III trial.
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